Vascular Biogenics (VBLT) Lowered to “Sell” at Zacks Investment Research
Zacks Investment Research downgraded shares of Vascular Biogenics (NASDAQ:VBLT) from a hold rating to a sell rating in a research report report published on Thursday.
According to Zacks, “Vascular Biogenics Ltd. is a clinical stage biotechnology company. It is focused on the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases. Its lead oncology candidate VB-111, is a gene-based biologic which is in Phase II clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer. It is also developing VB-201, an oral small molecule that is in Phase II clinical trials for the treatment psoriasis and ulcerative colitis. Vascular Biogenics Ltd. is headquartered in Or Yehuda, Israel. “
Other research analysts have also issued reports about the stock. HC Wainwright reissued a buy rating and set a $3.00 target price on shares of Vascular Biogenics in a research note on Tuesday, January 15th. ValuEngine raised shares of Vascular Biogenics from a sell rating to a hold rating in a research note on Thursday, January 3rd. Finally, Chardan Capital set a $3.00 target price on shares of Vascular Biogenics and gave the company a hold rating in a research note on Tuesday, March 19th.
An institutional investor recently bought a new position in Vascular Biogenics stock. RBF Capital LLC purchased a new position in Vascular Biogenics Ltd (NASDAQ:VBLT) in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 363,724 shares of the biopharmaceutical company’s stock, valued at approximately $353,000. RBF Capital LLC owned 1.01% of Vascular Biogenics at the end of the most recent quarter. Hedge funds and other institutional investors own 13.96% of the company’s stock.
Vascular Biogenics Company Profile
Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels.
Featured Story: How to read a candlestick chart
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.